0
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Commentary | 
Katherine E. Gundling, MD
Arch Intern Med. 1998;158(20):2185-2186. doi:10.1001/archinte.158.20.2185.

Sign In

Register for a FREE personal account

and access these and other features:

Register Now

Want to Subscribe?

Learn More about subscription options.

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Related JAMA Internal Medicine Topics
From The JAMA Network
JAMA
Viewpoint  | 
Codevelopment of Genome-Based Therapeutics and Companion Diagnostics:  Insights From an Institute of Medicine Roundtable
Robert T. McCormack, PhD; Joanne Armstrong, MD, MPH; Debra Leonard, MD, PhD
JAMA Ophthalmology
Original Investigation  | 
Safety and Effects of the Vector for the Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial
Rajeshwari D. Koilkonda, PhD; Hong Yu, PhD; Tsung-Han Chou, PhD; et al.
JAMA Ophthalmology
Original Investigation  | 
Trial End Points and Natural History in Patients With G11778A Leber Hereditary Optic Neuropathy :  Preparation for Gene Therapy Clinical Trial
Byron L. Lam, MD; William J. Feuer, MS; Joyce C. Schiffman, MS; et al.
JAMA Ophthalmology
Original Investigation  | 
Retinal Morphology of Patients With Achromatopsia During Early Childhood:  Implications for Gene Therapy
Paul Yang, MD, PhD; Keith V. Michaels, BS; Robert J. Courtney, MD; et al.